Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications

Published on Dec 6, 2018in ChemMedChem3.124
· DOI :10.1002/CMDC.201800624
Ruisi Fu1
Estimated H-index: 1
(Imperial College London),
Laurence Carroll19
Estimated H-index: 19
(Imperial College London)
+ 2 AuthorsPhilip W. Miller23
Estimated H-index: 23
(Imperial College London)
: Antibodies have long been recognised as potent vectors for carrying diagnostic medical radionuclides, contrast agents and optical probes to diseased tissue for imaging. The area of ImmunoPET combines the use of positron emission tomography (PET) imaging with antibodies to improve the diagnosis, staging and monitoring of diseases. Recent developments in antibody engineering and PET radiochemistry have led to a new wave of experimental ImmunoPET imaging agents that are based on a range of antibody fragments and affibodies. In contrast to full antibodies, engineered affibody proteins and antibody fragments such as minibodies, diabodies, single-chain variable region fragments (scFvs), and nanobodies are much smaller but retain the essential specificities and affinities of full antibodies in addition to more desirable pharmacokinetics for imaging. Herein, recent key developments in the PET radiolabelling strategies of antibody fragments and related affibody molecules are highlighted, along with the main PET imaging applications of overexpressed antigen-associated tumours and immune cells.
📖 Papers frequently viewed together
14 Citations
14 Citations
#1Eduardo Aluicio-Sarduy (UW: University of Wisconsin-Madison)H-Index: 11
#2Paul A. Ellison (UW: University of Wisconsin-Madison)H-Index: 13
Last. Jonathan W. Engle (UW: University of Wisconsin-Madison)H-Index: 30
view all 6 authors...
: Recent advances in molecular characterization of tumors have made possible the emergence of new types of cancer therapies where traditional cytotoxic drugs and nonspecific chemotherapy can be complemented with targeted molecular therapies. One of the main revolutionary treatments is the use of monoclonal antibodies (mAbs) that selectively target the disseminated tumor cells while sparing normal tissues. mAbs and related therapeutics can be efficiently radiolabeled with a wide range of radionuc...
17 CitationsSource
#1Amanda C. Freise (UCLA: University of California, Los Angeles)H-Index: 6
#2Kirstin A. Zettlitz (UCLA: University of California, Los Angeles)H-Index: 18
Last. Anna M. Wu (UCLA: University of California, Los Angeles)H-Index: 70
view all 9 authors...
: Inflammatory bowel diseases (IBDs) in humans are characterized in part by aberrant CD4-positive (CD4+) T-cell responses. Currently, identification of foci of inflammation within the gut requires invasive procedures such as colonoscopy and biopsy. Molecular imaging with antibody fragment probes could be used to noninvasively monitor cell subsets causing intestinal inflammation. Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET ...
25 CitationsSource
#1Patrícia M. R. Pereira (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 17
#2Lolkje Abma (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
Last. Jason S. LewisH-Index: 87
view all 4 authors...
Abstract The Human Epidermal Growth Factor Receptor (ErbB/HER) family - EGFR/HER1, ErbB-2/HER2, ErbB-3/HER3, and ErbB-4/HER4 - play a key role in tumor development. Moreover, positive status of HER2 and specific mutations of EGFR are necessary to initiate HER2 directed and EGFR mutation directed therapies. The status of these receptors is usually determined by assaying biopsy specimens of tumor tissues; however, tissue samples are insufficient to account for the complex dynamics and heterogeneit...
14 CitationsSource
As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based molecules in phase III and phase I/II clinical trials, respectively. These total 719 antibody-based clinical stage molecules include 493 naked IgGs, 87 antibody-drug conjugates, 61 bispecific antibodies, 37 total Fc fusion proteins, 17 radioimmunoglobulins, 13 antibody fragments, and 11 immunocytokines. New uses for these antibodies are ...
132 CitationsSource
#1Jason White (UC Davis: University of California, Davis)H-Index: 4
#2Lina Y. Hu (UC Davis: University of California, Davis)H-Index: 4
Last. Julie L. Sutcliffe (UC Davis: University of California, Davis)H-Index: 26
view all 4 authors...
Purpose Increased expression of the αvβ6 integrin correlates with advanced tumor grade and poor clinical outcome, identifying αvβ6 as a prognostic indicator and an attractive target for molecular imaging. This work investigated the ability of a disulfide-stabilized [64Cu]NOTA-αvβ6 cys-diabody to image αvβ6 expression in vivo using a nu/nu mouse model bearing human melanoma xenografts and positron-emission tomography.
6 CitationsSource
15 CitationsSource
#1Kirstin A. Zettlitz (UCLA: University of California, Los Angeles)H-Index: 18
#2Richard Tavaré (UCLA: University of California, Los Angeles)H-Index: 17
Last. Anna M. Wu (UCLA: University of California, Los Angeles)H-Index: 70
view all 6 authors...
Purpose: The B-cell antigen CD20 provides a target for antibody-based positron emission tomography (immunoPET). We engineered antibody fragments targeting human CD20 and studied their potential as immunoPET tracers in transgenic mice (huCD20TM) and in a murine lymphoma model expressing human CD20. Experimental Design: Anti-CD20 cys-diabody (cDb) and cys-minibody (cMb) based on rituximab (Rx) and obinutuzumab (GA101) were radioiodinated and used for immunoPET imaging of a murine lymphoma model. P...
25 CitationsSource
#1Clément BaillyH-Index: 14
Last. Jacques Barbet (University of Nantes)H-Index: 57
view all 6 authors...
Background Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranostic, combining PET imaging with short-lived positron emitters and therapy with radionuclides emitting beta or alpha particles.
18 CitationsSource
#1Saima Nawaz (St Thomas' Hospital)H-Index: 3
#2Gregory E. D. Mullen (St Thomas' Hospital)H-Index: 34
Last. James R. Ballinger (St Thomas' Hospital)H-Index: 28
view all 6 authors...
Background Labelling proteins with gallium-68 using bifunctional chelators is often problematic because of unsuitably harsh labelling conditions such as low pH or high temperature and may entail post-labelling purification. To determine whether tris(hydroxypyridinone) (THP) bifunctional chelators offer a potential solution to this problem, we have evaluated the labelling and biodistribution of a THP conjugate with a new single-chain antibody against the prostate-specific membrane antigen (PSMA),...
20 CitationsSource
#1Maria Iris Tsionou (St Thomas' Hospital)H-Index: 1
#2Caroline E. Knapp (UCL: University College London)H-Index: 13
Last. Michelle T. Ma (St Thomas' Hospital)H-Index: 16
view all 11 authors...
Gallium-68 (68Ga) is a positron-emitting isotope used for clinical PET imaging of peptide receptor expression. 68Ga radiopharmaceuticals used in molecular PET imaging consist of disease-targeting biomolecules tethered to chelators that complex 68Ga3+. Ideally, the chelator will rapidly, quantitatively and stably coordinate 68Ga3+ at room temperature, near neutral pH and low chelator concentration, allowing for simple routine radiopharmaceutical formulation. Identification of chelators that fulfi...
46 CitationsSource
Cited By17
#1Nairo Brilhante-da-Silva (FIOCRUZ: Oswaldo Cruz Foundation)
#2Rosa Maria de Oliveira Sousa (FIOCRUZ: Oswaldo Cruz Foundation)H-Index: 1
Last. Soraya dos Santos Pereira (UNIR: Universidade Federal de Rondônia)H-Index: 7
view all 0 authors...
The distinct biophysical and pharmaceutical properties of camelid single-domain antibodies, referred to as VHHs or nanobodies, are associated with their nanometric dimensions, elevated stability, and antigen recognition capacity. These biomolecules can circumvent a number of diagnostic system limitations, especially those related to the size and stability of conventional immunoglobulins currently used in enzyme-linked immunosorbent assays and point-of-care, electrochemical, and imaging assays. I...
Photodynamic therapy (PDT) is a well-documented therapy that has emerged as an effective treatment modality of cancers. PDT utilizes harmless light to activate non- or minimally toxic photosensitizers to generate cytotoxic species for malignant cell eradication. Compared with conventional chemotherapy and radiotherapy, PDT is appealing by virtue of the minimal invasiveness, its safety, as well as its selectivity, and the fact that it can induce an immune response. Although local illumination of ...
Site-specific conjugation of proteins is currently required to produce homogenous derivatives for medicine applications. Proteins derivatized at specific positions of the polypeptide chain can actually show higher stability, superior pharmacokinetics, and activity in vivo, as compared with conjugates modified at heterogeneous sites. Moreover, they can be better characterized regarding the composition of the derivatization sites as well as the conformational and activity properties. To this aim, ...
#3Anne-Sophie Beignon (French Institute of Health and Medical Research)
#5Nicolas Tchitchek (French Institute of Health and Medical Research)
Last. Pauline Maisonnasse (French Institute of Health and Medical Research)
view all 0 authors...
Vaccines represent one of the major advances of modern medicine. Despite the many successes of vaccination, continuous efforts to design new vaccines are needed to fight “old” pandemics, such as tuberculosis and malaria, as well as emerging pathogens, such as Zika virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccination aims at reaching sterilizing immunity, however assessing vaccine efficacy is still challenging and underscores the need for a better understanding of i...
#1Betül Altunay (RWTH Aachen University)H-Index: 1
#2Agnieszka Morgenroth (RWTH Aachen University)H-Index: 9
Last. Felix M. Mottaghy (UM: Maastricht University)H-Index: 72
view all 9 authors...
The aim of the present paper is to review the role of HER2 antibodies, affibodies and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a detailed look at recent clinical data from antibody drug conjugates and nanobodies as well as affibodies that are currently under development. Clinical and preclinical studies have shown that the use of monoclonal antibodies in molecular imaging is impaired by slow blood clearance, associated with slow and low tumor uptake a...
1 CitationsSource
#1Lei Kang (PKU: Peking University)H-Index: 16
#2Cuicui Li (PKU: Peking University)H-Index: 3
Last. Weibo Cai (UW: University of Wisconsin-Madison)H-Index: 91
view all 8 authors...
CD20-overexpressed non-Hodgkin lymphoma typically indicates progressive malignancy. Obinutuzumab is a next-generation Food and Drug Administration-approved humanized monoclonal antibody that targets CD20. Previous studies with 89Zr-labeled obinutuzumab have successfully imaged CD20 in vivo. However, delayed tumor uptake and increased radioactive exposure caused by long blood circulation limit its clinical translation. This study aimed to develop 64Cu-labeled F(ab')2 fragments of obinutuzumab for...
#1Federico Simonetta (Stanford University)H-Index: 16
#2Israt S. Alam (Stanford University)H-Index: 14
Last. Robert S. Negrin (Stanford University)H-Index: 94
view all 23 authors...
Purpose Immunomonitoring of chimeric antigen receptor (CAR) T cells relies primarily on their quantification in the peripheral blood, which inadequately quantifies their biodistribution and activation status in the tissues. Non-invasive molecular imaging of CAR T cells by positron emission tomography (PET) is a promising approach with the ability to provide spatial, temporal and functional information. Reported strategies rely on the incorporation of reporter transgenes or ex vivo biolabeling, s...
7 CitationsSource
#1Takahiro Morito (Tohoku University)
#2Ryuichi Harada (Tohoku University)H-Index: 25
Last. Kazuhiko Yanai (Tohoku University)H-Index: 74
view all 7 authors...
Brain positron emission tomography (PET) imaging with radiolabelled proteins is an emerging concept that potentially enables visualization of unique molecular targets in the brain. However, the pharmacokinetics and protein radiolabelling methods remain challenging. Here, we report the performance of an engineered, blood-brain barrier (BBB)-permeable affibody molecule that exhibits rapid clearance from the brain, which was radiolabelled using a unique fluorine-18 labelling method, a cell-free pro...
#1Violena PietrobonH-Index: 1
#2Alessandra Cesano (Sunesis Pharmaceuticals)H-Index: 1
Last. Jakob Nikolas Kather (RWTH Aachen University)H-Index: 17
view all 4 authors...
In recent years, cancer immunotherapy experienced remarkable developments and it is nowadays considered a promising therapeutic frontier against many types of cancer, especially hematological malignancies. However, in most types of solid tumors, immunotherapy efficacy is modest, partly because of the limited accessibility of lymphocytes to the tumor core. This immune exclusion is mediated by a variety of physical, functional and dynamic barriers, which play a role in shaping the immune infiltrat...
2 CitationsSource
#1Benjamin P. Burke (University of Hull)H-Index: 11
#2Stephen J. Archibald (University of Hull)H-Index: 25